Orphazyme: Anticipated product approval to secure transformational year

Orphazyme predicts lower operating result in transformational 2021.

Photo: Orphazyme/PR

Danish biotechnology firm Orphazyme, which develops medication for rare diseases, forecasts an operating deficit at DKK 100m-150m (USD 16.2m-24.2m) in 2021, which is significantly lower than the realized deficit for 2020 at DKK 608m, according to the firm's 2020 annual report.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs